Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.
Finding a treatment or cure for myotonic dystrophy can't happen without uniquely qualified individuals who are dedicated to the cause. The exceptional people we call on each day are what keep us moving forward towards treatments.
Board of Directors
The Foundation's Board of Directors is comprised of leaders in science, finance, fundraising, advocacy and non-profit leadership. Their expertise helps our work, assess our impact, and guide our pursuit of patient-relevant outcomes.
Medical and Scientific Advisory Committee
The Foundation's Medical and Scientific Advisory Committee is a group of leading myotonic dystrophy specialists and researchers from around the globe. Our advisors provide guidance, grant peer reviews, and speak at our annual family conference.
The Foundation's staff leads the day-to-day operations of our organization, and works with the board to set and execute our strategic agenda.